These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies. Zhao M Int J Antimicrob Agents; 2020 Jun; 55(6):105982. PubMed ID: 32305588 [TBL] [Abstract][Full Text] [Related]
3. Weathering the Cytokine Storm in COVID-19: Therapeutic Implications. Iannaccone G; Scacciavillani R; Del Buono MG; Camilli M; Ronco C; Lavie CJ; Abbate A; Crea F; Massetti M; Aspromonte N Cardiorenal Med; 2020; 10(5):277-287. PubMed ID: 32599589 [TBL] [Abstract][Full Text] [Related]
4. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Soy M; Keser G; Atagündüz P; Tabak F; Atagündüz I; Kayhan S Clin Rheumatol; 2020 Jul; 39(7):2085-2094. PubMed ID: 32474885 [TBL] [Abstract][Full Text] [Related]
5. Immunomodulatory Drugs in the Management of SARS-CoV-2. Burrage DR; Koushesh S; Sofat N Front Immunol; 2020; 11():1844. PubMed ID: 32903555 [TBL] [Abstract][Full Text] [Related]
6. Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review. Quirch M; Lee J; Rehman S J Med Internet Res; 2020 Aug; 22(8):e20193. PubMed ID: 32707537 [TBL] [Abstract][Full Text] [Related]
7. Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab. Langer-Gould A; Smith JB; Gonzales EG; Castillo RD; Figueroa JG; Ramanathan A; Li BH; Gould MK Int J Infect Dis; 2020 Oct; 99():291-297. PubMed ID: 32768693 [TBL] [Abstract][Full Text] [Related]
8. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. Wang J; Jiang M; Chen X; Montaner LJ J Leukoc Biol; 2020 Jul; 108(1):17-41. PubMed ID: 32534467 [TBL] [Abstract][Full Text] [Related]
10. Tackling the cytokine storm in COVID-19, challenges and hopes. Abdin SM; Elgendy SM; Alyammahi SK; Alhamad DW; Omar HA Life Sci; 2020 Sep; 257():118054. PubMed ID: 32663575 [TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review. Alijotas-Reig J; Esteve-Valverde E; Belizna C; Selva-O'Callaghan A; Pardos-Gea J; Quintana A; Mekinian A; Anunciacion-Llunell A; Miró-Mur F Autoimmun Rev; 2020 Jul; 19(7):102569. PubMed ID: 32376394 [TBL] [Abstract][Full Text] [Related]
12. Thoughts on COVID-19 and autoimmune diseases. Askanase AD; Khalili L; Buyon JP Lupus Sci Med; 2020; 7(1):e000396. PubMed ID: 32341791 [TBL] [Abstract][Full Text] [Related]
13. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Jamilloux Y; Henry T; Belot A; Viel S; Fauter M; El Jammal T; Walzer T; François B; Sève P Autoimmun Rev; 2020 Jul; 19(7):102567. PubMed ID: 32376392 [TBL] [Abstract][Full Text] [Related]
15. The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection. Copaescu A; Smibert O; Gibson A; Phillips EJ; Trubiano JA J Allergy Clin Immunol; 2020 Sep; 146(3):518-534.e1. PubMed ID: 32896310 [TBL] [Abstract][Full Text] [Related]
16. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19. Seif F; Aazami H; Khoshmirsafa M; Kamali M; Mohsenzadegan M; Pornour M; Mansouri D Int Arch Allergy Immunol; 2020; 181(6):467-475. PubMed ID: 32392562 [TBL] [Abstract][Full Text] [Related]
17. The role of Interleukin 6 inhibitors in therapy of severe COVID-19. Nasonov E; Samsonov M Biomed Pharmacother; 2020 Nov; 131():110698. PubMed ID: 32920514 [TBL] [Abstract][Full Text] [Related]
18. Immunomodulatory Therapeutic Proteins in COVID-19: Current Clinical Development and Clinical Pharmacology Considerations. Ji P; Chen J; Golding A; Nikolov NP; Saluja B; Ren YR; Sahajwalla CG J Clin Pharmacol; 2020 Oct; 60(10):1275-1293. PubMed ID: 32779201 [TBL] [Abstract][Full Text] [Related]